Is a GLP-1 worth it at $299 a month? The honest answer is that the number on the checkout page answers almost nothing by itself. Worth depends on what the fee actually covers, what the medicine costs separately, whether anyone measures your results and whether the people managing your treatment earn anything from your dose going up. We will give you all four answers for our membership in this article, because you should be able to do this arithmetic yourself before you ever hand over a card number.
- The Cardiometabolic Optimization Membership is one flat $299 a month after a first charge of $598 covering the first two months combined.
- The fee covers the doctor and the labs only. Medication is a separate charge billed by your pharmacy at pharmacy cost with zero markup from us.
- Published self-pay prices as of late 2026 run from $149 to $499 a month for branded options depending on the molecule, the dose and the program.
- The worth-it test has three parts: does the fee include diagnosis, does anyone re-test the plan and does anyone profit from escalation.
- Trial averages are roughly 15 percent of body weight on semaglutide in STEP 1 and up to about 22.5 percent on tirzepatide in SURMOUNT-1, with individual results varying widely.
What the $299 actually buys
Start with what the fee is, because a surprising number of weight-loss platforms bury this. Our fee covers the clinical relationship and nothing else. Concretely, that is the intake visit where a clinician takes your full history, the comprehensive Biomarker Audit that runs every 90 days through the Beluga Health lab network, the written protocol that comes out of those results, the monthly check-ins between audits and a clinician who answers when something changes between appointments.
The first charge at checkout is $598. That is one charge covering the first two months together: the clinical intake, the first comprehensive panel, the protocol built from it and the second month of care while treatment begins. It is not $299 plus $598. It is one combined amount. From month three the membership is $299 a month and you can cancel anytime after the initial commitment.
Where the money goes
what each charge covers
| Charge | Amount | What it covers |
|---|---|---|
| First charge | $598 once | Clinical intake, first Biomarker Audit, written protocol and month 2 of care |
| Monthly fee | $299 a month | Quarterly Biomarker Audits, monthly check-ins, clinical care and message access |
| Medication | Pharmacy bill, separate | Billed by your pharmacy at its own price, with zero markup from us |
What the medicine costs, separately and honestly
The fee never includes the medicine and we want that said without hedging, because a membership that quietly bundles a marked-up drug is the model we built against. When your clinician prescribes, your pharmacy bills you directly at its own price. We take nothing from that transaction. No molecule upcharge, no dose-escalation fee and no handling margin of any kind.
What will that bill look like? Manufacturer-published self-pay figures as of late 2026, which we cite with the caveat that prices change: Wegovy pens run $199 a month for the first two fills as an introductory offer and $349 a month after. Zepbound vials sell through LillyDirect at roughly $299 to $449 depending on dose. Ozempic self-pay runs $199 to $499 depending on dose and patient status and Foundayo, the daily oral option, starts at $149 a month. Your actual pharmacy bill may differ and we will never know or influence it.
That separation is not a pricing gimmick. It is the mechanism that keeps the clinical advice honest, because when nobody in the chain earns a dollar from the prescription, declining, deprescribing and referring become normal clinical acts rather than revenue threats.
The three questions that decide whether any GLP-1 plan is worth it
Whatever program you are considering, ours or anyone's, these three questions carry almost all of the decision.
First: does the fee include diagnosis? A program that prescribes in a day with no labs is not cheaper medicine. It is medicine without a diagnosis, which means nobody knows whether your weight problem is a GLP-1 problem at all. Thyroid dysfunction, insulin resistance, perimenopausal hormone shifts and low testosterone all produce stubborn weight and each one has its own treatment. Prescribing before measuring is guessing with your money.
Second: does anyone re-test the plan? Treatment that never gets re-measured is treatment defended rather than evaluated. Our Biomarker Audit repeats the full panel every 90 days and every dose conversation happens against that trend, so a plan that is not working gets revised on evidence rather than on patience.
Third: does anyone profit from your dose climbing? This is the question the weight-loss industry least wants asked. Dose-escalation platforms commonly reprice as you titrate, with maintenance-tier pricing commonly reported in the $600 to $899 a month range on the larger platforms. We hedge those figures because they are reported across programs rather than printed on one page, but the structure is not in dispute: when margin lives inside the medication, the dose goes up and the bill goes with it. Our fee is the same $299 at every dose and every molecule, so the answer to the dose question here is never a revenue answer.
Ask what would make your dose come down. A program with an honest answer is worth its fee at almost any price. A program with no answer is selling a prescription rather than a plan.
What the evidence says the medication can do
You deserve the trial numbers stated plainly, with the honest caveat attached. In STEP 1, adults taking weekly semaglutide lost an average of roughly 15 percent of body weight over 68 weeks against about 2 percent for placebo. In SURMOUNT-1, the highest dose of weekly tirzepatide produced average losses of up to about 22.5 percent at 72 weeks. Those are averages across thousands of participants and individual results vary widely. No medication carries a guaranteed result and no trial tested the compounded copies some platforms still sell, which is one more reason we prescribe branded, FDA-approved medication only: Wegovy, Zepbound, Ozempic, Mounjaro, Wegovy Tablets and Foundayo.
There is a further point that matters for the worth-it question. Most of the benefit in the trials arrives before the top dose, while side effects keep rising with it. If you are the kind of patient who wants the lowest dose that holds your result, a flat fee is not a luxury. It is the thing that makes that preference safe to have.
The cheapest option is rarely the cheapest plan
We will not pretend the cheap platforms sell nothing real. Some people get a legitimate prescription from them and do fine. But look at what the headline price leaves out, because the missing pieces are exactly where the value lives. There are no comprehensive labs, so nobody catches the thyroid or the insulin picture. There is no body-composition monitoring, so muscle loss goes unnoticed. There is no quarterly re-testing, so a failing plan runs for a year before anyone notices. And there is no structural reason for anyone to tell you when you are on more medicine than you need.
Our membership is built for the person who has already tried the cheap version and watched the dose climb with the bill. If that is your history, our guide to the dose-escalation trap walks through how that pricing structure works and the true monthly cost of GLP-1 telehealth lays the numbers side by side.
Who should not pay for this
Honesty requires this section. If you want a prescription renewed without labs and a dose raised on request, we are the wrong clinic. If you are looking for the lowest possible monthly number and nothing else, a prescription-only platform will beat our fee on the sticker and you should understand exactly what you are trading away when you choose it. And if your weight, your glucose and your lipids are all trending well on a plan you already trust, there is no reason to change anything.
If instead you want a clinician who names the mechanism, treats it and proves the treatment worked on labs, start with the eligibility assessment. It comes before checkout and before any charge. A clinician reviews every application because not everyone is accepted.
FAQ
Is a GLP-1 worth it at $299 a month? It is worth it when the fee covers diagnosis and clinical care, the medication is billed at pharmacy cost with no markup and the plan is re-tested on labs every 90 days. If your alternative is a bare prescription with no labs, the cheaper headline price usually buys less medicine rather than more value.
What does the $598 first charge cover? It is one charge covering the first two months together: the clinical intake, the first comprehensive Biomarker Audit, the protocol built from those results and the second month of care. From month three the membership is $299 a month and you can cancel anytime after the commitment.
How much does the medicine cost on top of the fee? Your pharmacy bills you directly at its own price. Published self-pay figures as of late 2026 include Wegovy at $199 for the first two fills and $349 after, Zepbound vials at roughly $299 to $449 and Ozempic at $199 to $499 depending on dose. Confirm current prices before relying on any figure.
Why not just use a cheaper platform? Cheaper platforms commonly earn their margin inside the medication and have no reason to run the labs that might end a prescription. A lower headline price without diagnosis and re-testing is a different product with less in it rather than the same product cheaper.
How much weight can I expect to lose? Trial averages are about 15 percent of body weight on semaglutide in STEP 1 and up to about 22.5 percent on the highest tirzepatide dose in SURMOUNT-1. Individual results vary widely and no result is guaranteed.
Can I cancel if it is not working? Yes. After the initial commitment the membership is month to month. The quarterly Biomarker Audit exists so a plan that is not working gets revised on evidence rather than defended on patience.
What if I do not need medication at all? Then the protocol says so and you skip the pharmacy bill entirely. Because nobody in our chain earns anything from a prescription, recommending against medication costs us nothing and costs you everything you would have overpaid.
Related Reading
- The true monthly cost of GLP-1 telehealth
- The GLP-1 dose-escalation trap
- Biomarker audits vs standard blood tests
- Medical weight loss at GoodLife Health
References
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1, New England Journal of Medicine). 2021. pubmed.ncbi.nlm.nih.gov/33567185/
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, New England Journal of Medicine). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- NovoCare Pharmacy: Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html